New Eloxatin® and TAXOTERE® Research to be Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

New Eloxatin® and TAXOTERE® Research to be Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) ~ More than 200 Studies of Two Leading Chemotherapy Treatments in some of the Most Common and Difficult to Treat Cancers to be Featured at the Meeting ~ Paris, May 10, 2005 – The sanofi-aventis Group announced today that important results from Eloxatin® (oxaliplatin for injection) and Taxotere® (docetaxel) Injection Concentrate clinical studies, including studies on colorectal, breast, lung, prostate and gastric cancer, will be presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting begins on May 13 and runs through May 17, in Orlando, Florida. A total of 220 abstracts for studies involving Eloxatin® and Taxotere® will be published, with seven Eloxatin® and 10 Taxotere® abstracts selected for discussion during the meeting’s oral presentation sessions. In particular, one Eloxatin® abstract will be part of the Society’s Plenary Presentation on Saturday, May 14. Among the data to be presented at the meeting are the following: Eloxatin® clinical studies results A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07 Monday, May 16, 2005, 7:45 – 8:00 a.m., Gastrointestinal (Colorectal) Cancer Oral Presentation. Abstract #LBA3500 Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow up of 4 years Monday, May 16, 2005, 8:00 – 8:15 a.m., Gastrointestinal (Colorectal) Cancer Oral Presentation. Abstract #3501 High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 Saturday, May 14, 2005, 4:40 – 4:55 p.m., Plenary Session 1. Abstract #2 Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies Tuesday, May 17, 2005, 11:00 – 12:15 p.m., Gastrointestinal (Colorectal) Cancer Poster Discussion Session, Poster #5. Abstract #3514 Cetuximab in combination with oxaliplatin/5-Fluorouracil (56FU) folinic acid (FA) (FOLFOX) in the first line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase 2 Study Saturday May 14, 2005, 2:00 – 6:00 p.m., Gastrointestinal Poster Session. Abstract #3535 Taxotere® clinical studies results Final Results of TAX325, a randomized controlled phase III trial comparing Taxotere combined with cisplatin (C) and 5-fluorouacil (F) to CF in patients with metastatic gastric adenocarcinoma (MGC) Sunday, May 15, 2005, 2:45 – 3:00 p.m., Gastrointestinal (Noncolorectal) Cancer Oral Presentation. Abstract #4002 Phase I/II study of docetaxel (DOC) and S-1 for patients (pts) with advanced gastric cancer (AGC) Saturday, May 16, 2005, 2:00 – 6:00 p.m., Gastrointestinal (Noncolorectal) Cancer General Poster Session. Poster #K9. Abstract #4064 SWOG 0023 – Analysis of an ongoing Phase III trial of concurrent chemoradiotherapy followed by consolidation Taxotere® and gefitinib/placebo maintenance in patients with inoperable stage III non-small cell lung cancer Monday, May 16, 2005, 3:45 – 4:00 p.m., Lung Cancer Oral Presentation. Abstract #7058 SWOG 9504 – Long-term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation Taxotere® following concurrent chemoradiotherapy Monday, May 16, 2005 11:00 a.m. – 12:00 p.m., Lung Cancer II Poster Discussion Session, Poster #9. Abstract #7059 About Eloxatin® In Europe Eloxatin® received approval in France for the second-line treatment of metastatic colorectal cancer in April 1996, and as a first-line treatment in April 1998. In July 1999, Eloxatin® was approved for the first-line treatment of advanced colorectal cancer in major European countries through the Mutual Recognition Procedure, France being the Reference Member State. Eloxatin® successfully completed a Mutual Recognition Procedure in Europe in December 2003, which allowed the product to be marketed for the treatment of metastatic colorectal cancer in combination with 5-fluorouracil and folinic acid (i.e., in first- and second-line treatment). In September 2004, the indication for Eloxatin® was extended in Europe, again through the Mutual Recognition Procedure, to include the “Adjuvant treatment of stage III (Dukes’ C) colon cancer after complete resection of primary tumor.” In the United States In the United States, Eloxatin®, in combination with infusional 5-FU/LV, received approval on January 9, 2004, for the first-line treatment of advanced carcinoma of the colon or rectum (ie, first therapy for patients with metastatic colorectal cancer). This same Eloxatin®-based combination had initially (August 2002) received FDA approval for second-line treatment, (ie, therapy for previously treated patients with metastatic colorectal cancer). On November 4, 2004, this Eloxatin®-based regimen was approved for the adjuvant treatment of stage III (Dukes’ C) colon cancer after complete resection of the primary tumor. Eloxatin® was developed in association with Debiopharm SA and is currently marketed by sanofi-aventis in more than 60 countries. Further Development in Other Types of Cancer An extensive worldwide clinical development program is ongoing to explore the potential benefits of Eloxatin® (oxaliplatin for injection) in other types of cancer. About Taxotere® Taxotere® (docetaxel), a drug in the taxoid class of chemotherapeutic agents, inhibits cancer cell division by essentially “freezing” the cell’s internal skeleton, which is comprised of microtubules. Microtubules assemble and disassemble during a cell cycle. Docetaxel promotes their assembly and blocks their disassembly, thereby preventing many cancer cells from dividing and resulting in death in some cancer cells. Taxotere® is indicated for early stage and metastatic breast cancer, non-small cell lung cancer, and androgen-independent (hormone-refractory) metastatic prostate cancer. Taxotere® is being studied extensively in clinical trials for safety and efficacy in Head and Neck and gastric cancers. About sanofi-aventis Sanofi-aventis is the world’s 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, vaccines. ------------------------------------------------------------ Informasjonen er sendt gjennom Waymaker http://www.waymaker.no Nedenstående filer kan lastes ned: http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=97226&fn=wkr0001.pdf Pressemeldingen i pdf-format